Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Cellinfinity Bio

Company Type: Therapeutics

Main focus: Gene-edited immune cells, e.g., natural killer cells and T cells.

Company stage: Pre-clinical

Diseases: multiple malignancies, including solid tumours

Genome-editing tool: CRISPR/Cpf1

Funding stage: Seeding

Location: West Haven, CT, USA




Cellinfinity Bio is a pre-clinical company focused on CRISPR-based engineering of immune cells, such as T cells and natural killer (NK) cells, to generate chimeric antigen receptors (CARs) targeted against multiple malignancies including solid tumours. By leveraging proprietary methods for directed evolution of cells, Cellinfinity identifies genetic modifications and CAR constructs that substantially improve engineered T-cell and NK-cell activities against solid tumours. Cellinfinity develops both first-in-class and best-in-class cell therapy products with the goal to benefit diverse patient populations with unmet medical needs.


HashtagCellinfinity Bio

Company: Cellinfinity Bio
Search CRISPR Medicine